Nova (NOVA)

Most subnets talk about long-term thinking.

NOVA just proved it with a wallet.

50% of company tokens locked before conviction even rolled out.

Founder allocations are structured so each individual position stays below the top 10 holders after tax.

Owner's cut automatically locked going forward so conviction only grows over time.

This is not a roadmap item. This is on-chain commitment with real skin in the game from four founders who tied their personal upside directly to subnet growth.

Now read what is underneath the tokenomics.

NOVA is not building a trading tool or a content generator.

They are building AI infrastructure for drug discovery.

The problems they are solving have multi-year timelines and billions in implications for how medicine gets made.

Since launching, they have shipped 3 incentive mechanisms, established 3 partnerships with biotech companies outside the Bittensor ecosystem entirely, provided open-source access to fine-tuned state of the art models, and run ongoing screening campai

NOVA Conviction Update + Incentive Alignment

We didn't choose drug discovery because it was an easy or fast problem to solve. We chose it because it's one of the hardest and most meaningful problems AI can tackle. Our ambition and track record reflects our commitment to long‑term value creation.

Since launching, NOVA has shipped 3 incentive mechanisms, established 3 relevant partnerships with other biotech companies outside of the Bittensor ecosystem, provided open‑source access to optimized and fine‑tuned SOTA models, run ongoing screening campaigns across multiple therapeutic modalities, and much more.

That work has been funded by token sales and it will continue on multi‑year timelines regardless of short‑term price action. As the conviction mechanism rolls out across Bittensor, we want to be transparent about how we're approaching it by locking company tokens and aligning founder incentives with subnet growth.

Company Wallet — 50% Locked
Even before conviction, we've always balanced self‑financing wit